SAN FRANCISCO, March 20, 2019 /PRNewswire/ -- Lexent Bio, a precision oncology company developing a novel liquid biopsy system, today announced that Ted Snelgrove has joined the company as Chief Business Officer. With more than 30 years of commercialization experience bringing novel products into both therapeutic and diagnostic markets, Mr. Snelgrove will work closely with the CEO and Board to drive launch strategy, commercial team development and corporate partnering for the company.
Lexent Bio develops advanced liquid biopsy technology for measuring and monitoring drug response in later-stage cancer patients to let clinicians monitor response to therapy faster than imaging and more accurately than is currently possible, to quickly identify the most effective treatment.
"Throughout his career, Ted has led changes in clinical practice in oncology, at Genomic Health, Amgen and beyond," said Ken Nesmith, cofounder and CEO of Lexent Bio. "We seek to build new tools that change the way we treat cancer, improving outcomes for patients. As we plan the launch of our first response monitoring products, patients and their clinicians need us to solve critical product and go-to-market decisions. Ted, together with our clinical team, will lead this work."
Mr. Snelgrove has deep experience in the molecular diagnostic sector, having built and led the original commercial team at Genomic Health that created and launched the Oncotype DX product line. He later built the commercial team at Crescendo Bioscience, now part of Myriad Genetics, where his team developed Vectra DA for disease management in rheumatology. Ted also served as CEO at CellScape, an early player in the NIPT market. Ted was the Oncology/Hematology Business Unit Head at Jazz Pharmaceuticals, where he led a newly-formed division focused on hematologic malignancies and stem cell transplant. He also held C-Level roles at Counsyl, where he worked with the founders to position the firm for an exit, again with Myriad, and more recently at Guardant Health. He got his start in the industry at Eli Lilly and progressed through commercial and strategy roles at Immunex, Amgen and ALZA. He received an MBA from the University of Michigan and previously served as an officer in the US Navy.
"I'm excited to join Lexent Bio at this exciting and formative stage. The feedback loop in cancer treatment has not yet been optimized for the best outcomes – at the level of the individual -- and is often limited by existing technologies. Lexent is building tools that promise to deliver actionable insights at critical decision points," said Snelgrove. "I look forward to working with members of the Lexent team, many of whom I've worked with before, as we prepare to bring new solutions to the oncology market."
Dr. Haluk Tezcan, Lexent's co-founder and Chief Medical Officer, noted that the timing of Ted joining the company is perfectly matched to development progress recently achieved. Lexent has begun publishing on its methods and results, at AGBT Precision Medicine last year, AGBT General Meeting in February, and at the upcoming AACR annual meeting. "Now that we've developed our technology extensively via prospective clinical trials to pressure-test the technology and ensure it's ready for regular clinical use, Ted's leadership will be critical to the next phases of product launch and company growth."
About Lexent BioLexent Bio is a precision oncology company. The company aims to shrink cancer's role in our lives, first by helping patients and their clinicians make better treatment decisions, faster. A team of highly accomplished, purpose-driven individuals, the Lexent Bio team hails from clinical, scientific, engineering, computer science, and business backgrounds, and share a passion for changing the way we understand and treat cancer. The company is taking on some of the hardest problems at the intersection of unexplored cancer biology, data science, and clinical medicine, and has raised over $12m from some of the world's leading investors including Threshold Ventures (formerly DFJ), Correlation Ventures, Charge Ventures, Goodman Capital, and others.
Advertisement
Lexent Bio develops advanced liquid biopsy technology for measuring and monitoring drug response in later-stage cancer patients to let clinicians monitor response to therapy faster than imaging and more accurately than is currently possible, to quickly identify the most effective treatment.
Advertisement
"Throughout his career, Ted has led changes in clinical practice in oncology, at Genomic Health, Amgen and beyond," said Ken Nesmith, cofounder and CEO of Lexent Bio. "We seek to build new tools that change the way we treat cancer, improving outcomes for patients. As we plan the launch of our first response monitoring products, patients and their clinicians need us to solve critical product and go-to-market decisions. Ted, together with our clinical team, will lead this work."
Mr. Snelgrove has deep experience in the molecular diagnostic sector, having built and led the original commercial team at Genomic Health that created and launched the Oncotype DX product line. He later built the commercial team at Crescendo Bioscience, now part of Myriad Genetics, where his team developed Vectra DA for disease management in rheumatology. Ted also served as CEO at CellScape, an early player in the NIPT market. Ted was the Oncology/Hematology Business Unit Head at Jazz Pharmaceuticals, where he led a newly-formed division focused on hematologic malignancies and stem cell transplant. He also held C-Level roles at Counsyl, where he worked with the founders to position the firm for an exit, again with Myriad, and more recently at Guardant Health. He got his start in the industry at Eli Lilly and progressed through commercial and strategy roles at Immunex, Amgen and ALZA. He received an MBA from the University of Michigan and previously served as an officer in the US Navy.
"I'm excited to join Lexent Bio at this exciting and formative stage. The feedback loop in cancer treatment has not yet been optimized for the best outcomes – at the level of the individual -- and is often limited by existing technologies. Lexent is building tools that promise to deliver actionable insights at critical decision points," said Snelgrove. "I look forward to working with members of the Lexent team, many of whom I've worked with before, as we prepare to bring new solutions to the oncology market."
Dr. Haluk Tezcan, Lexent's co-founder and Chief Medical Officer, noted that the timing of Ted joining the company is perfectly matched to development progress recently achieved. Lexent has begun publishing on its methods and results, at AGBT Precision Medicine last year, AGBT General Meeting in February, and at the upcoming AACR annual meeting. "Now that we've developed our technology extensively via prospective clinical trials to pressure-test the technology and ensure it's ready for regular clinical use, Ted's leadership will be critical to the next phases of product launch and company growth."
About Lexent BioLexent Bio is a precision oncology company. The company aims to shrink cancer's role in our lives, first by helping patients and their clinicians make better treatment decisions, faster. A team of highly accomplished, purpose-driven individuals, the Lexent Bio team hails from clinical, scientific, engineering, computer science, and business backgrounds, and share a passion for changing the way we understand and treat cancer. The company is taking on some of the hardest problems at the intersection of unexplored cancer biology, data science, and clinical medicine, and has raised over $12m from some of the world's leading investors including Threshold Ventures (formerly DFJ), Correlation Ventures, Charge Ventures, Goodman Capital, and others.
View original content:http://www.prnewswire.com/news-releases/lexent-bio-appoints-ted-snelgrove-as-chief-business-officer-300815387.html
SOURCE Lexent Bio
